A Multinational, Investigator-initiated, Parallel Group, Randomised, Double-blind, Placebo-controlled Phase 3b Superiority Trial Assessing the Effect of Dupilumab on Inducing Clinical Remission Outcomes in At-risk Type-2 Inflammatory Asthma (HOTHOT)
Latest Information Update: 06 Jan 2026
At a glance
- Drugs Dupilumab (Primary)
- Indications Asthma
- Focus Therapeutic Use
- Acronyms HOTHOT
Most Recent Events
- 06 Jan 2026 New trial record